Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0076-6879(94)41067-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction: Tat protein is a trans-activator of HIV-1 genome transcription, with additional functions including the ability to induce the chronic inflammatory process. Natural amino acid polymorphisms in Tat may affect its functional properties and the course of HIV infection. The aim of this work is to analyze the marks of Tat consensus sequences in non-A6 HIV-1 variants characteristic of the Russian Federation, as well as study natural polymorphisms in Tat CRF63_02A6 and subtype B variants circulating in Russia.
View Article and Find Full Text PDFHuman Endogenous Retrovirus K in Astrocytes Is Altered in Parkinson's Disease.
Mov Disord
January 2025
Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia.
Background: Parkinson's disease (PD) is the most common neurodegenerative movement disease. Human endogenous retroviruses (HERVs) are proviral remnants of ancient retroviral infection of germ cells that now constitute about 8% of the human genome. Under certain disease conditions, HERV genes are activated and partake in the disease process.
View Article and Find Full Text PDFA dual-mode colorimetric/photothermal lateral flow biosensor based on Au/TiCT for HIV-DNA detection.
Anal Chim Acta
February 2025
Ministry of Education Key Laboratory for the Synthesis and Application of Organic Functional Molecules, Hubei Key Laboratory for Precision Synthesis of Small Molecule Pharmaceuticals, College of Chemistry and Chemical Engineering, Hubei University, Wuhan, 430062, PR China; Key Laboratory of Advanced Energy Materials Chemistry (Ministry of Education), Nankai University, Tianjin, 300071, PR China. Electronic address:
Background: Traditional lateral flow biosensors (LFBs), which utilize colorimetric signals as output, possess the virtues of simplicity and rapidity. However, it also suffers from insufficient sensitivity and limited reliability. It is well known that the results of LFBs can be false positive, and it is difficult to perform accurate quantification under low-abundance targets.
View Article and Find Full Text PDFRetrovirus-based manufacturing of chimeric antigen receptor-modified T cells for cancer therapy research.
Methods Cell Biol
January 2025
Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, A Partnership Between the DKFZ Heidelberg and LMU University Hospital, Munich, Germany; Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany. Electronic address:
Treatment with autologous chimeric antigen receptor (CAR)-modified T cells can achieve outstanding clinical response rates in heavily pretreated patients with B and plasma cell malignancies. However, relapses occur, and they limit the efficacy of this promising treatment approach. The complex GMP-compliant production and high treatment costs cause that CAR T cells cannot yet be used in a broad population.
View Article and Find Full Text PDFPrevalence of major INSTI and HIV-1 drug resistance mutations in pre- and antiretroviral-treated patients in Indonesia.
Narra J
December 2024
Department of Clinical Pathology, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
Indonesia has one of the highest HIV infection rates in Southeast Asia. The use of dolutegravir, an integrase strand transfer inhibitor (INSTI), as a first-line treatment underscores the need for detailed data on INSTI drug resistance mutations (DRMs). Currently, there is a lack of comprehensive data on DRMs INSTI and other HIV drug resistance in Indonesian patients, both pre- and post-treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!